Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  2,678 results for ""MYELODYSPLASTIC syndromes""

Your Filters

Subject : azacitidine
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.

  • Authors : DiNardo CD; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Verma D

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Glutaminase*/Glutaminase*/Glutaminase*/antagonists & inhibitors ; Azacitidine*/Azacitidine*/Azacitidine*/therapeutic use

  • Source: Nature cancer [Nat Cancer] 2024 Oct; Vol. 5 (10), pp. 1515-1533. Date of Electronic Publication: 2024 Sep 19.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes.

  • Authors : Gulei D; Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.; Moisoiu V

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/pathology

  • Source: Journal of cellular and molecular medicine [J Cell Mol Med] 2024 Sep; Vol. 28 (18), pp. e70078.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101083777 Publication Model: Print Cited Medium: Internet ISSN: 1582-4934

Record details

Read More Add to Saved list
×
Academic Journal

[Efficacy and Safety of Reduced Dose Azacitidine in the Treatment of Elderly Patients with Myelodysplastic Syndromes].

  • Authors : Zhang C; Department of Hematology, Huaibei Miners General Hospital, Huaibei 235000, Anhui Province, China.; Sun C

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Azacitidine*/Azacitidine*/Azacitidine*/administration & dosage; Humans

  • Source: Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2024 Aug; Vol. 32 (4), pp. 1160-1164.Publisher: Zhongguo shi yan xue za zhi she Country of Publication: China NLM ID: 101084424 Publication Model: Print Cited Medium: Print ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.

  • Authors : Noguera-Castells A; Cancer Epigenetics Group, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain.; Department of Biosciences, Faculty of Science, Technology and Engineering, University of Vic - Central University of Catalonia (UVic-UCC), Vic, Barcelona, Catalonia, Spain.

Subjects: Azacitidine*/Azacitidine*/Azacitidine*/therapeutic use ; Azacitidine*/Azacitidine*/Azacitidine*/pharmacology ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy

  • Source: British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1838-1843. Date of Electronic Publication: 2024 Mar 12.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/drug therapy ; Azacitidine*/Azacitidine*/Azacitidine*/pharmacokinetics

  • Source: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Jun; Vol. 30 (4), pp. 721-736. Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine.

  • Authors : Tasis A; Translational Research and Laboratory Medicine Unit, First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.; Department of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.

Subjects: CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/immunology ; CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/CD8-Positive T-Lymphocytes*/drug effects ; Azacitidine*/Azacitidine*/Azacitidine*/therapeutic use

  • Source: Cancer research communications [Cancer Res Commun] 2024 Dec 01; Vol. 4 (12), pp. 3067-3083.Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

CD34 Chimerism Directed Donor Lymphocyte Infusion With or Without Azacitidine Results in Reduced Relapse and Superior Overall Survival When Full Donor Chimerism is Achieved in Allogeneic Stem Cell Transplant Recipients With Acute Myeloid Leukaemia/Myelodysplastic Syndrome.

  • Authors : Tan JL; Department of Malignant Haematology, Transplantation and Cellular Therapies, The Alfred Hospital, Victoria, Australia. Electronic address: .; Curtis DJ

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/mortality ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy

  • Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Nov; Vol. 24 (11), pp. e852-e860. Date of Electronic Publication: 2024 Jul 20.Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.

  • Authors : Matsumoto T; Basic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.; Murakami Y

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Azacitidine*/Azacitidine*/Azacitidine*/therapeutic use

  • Source: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 23; Vol. 25 (9). Date of Electronic Publication: 2024 Apr 23.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Read More Add to Saved list
×
Academic Journal

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Subjects: Azacitidine*/Azacitidine*/Azacitidine*/pharmacology ; Azacitidine*/Azacitidine*/Azacitidine*/therapeutic use ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics

  • Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Apr; Vol. 24 (4), pp. 260-268.e2. Date of Electronic Publication: 2023 Dec 20.Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.

  • Authors : Huang C; Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Jia Y

Subjects: Azacitidine*/Azacitidine*/Azacitidine*/therapeutic use ; Azacitidine*/Azacitidine*/Azacitidine*/adverse effects ; Azacitidine*/Azacitidine*/Azacitidine*/administration & dosage

  • Source: British journal of haematology [Br J Haematol] 2024 Sep; Vol. 205 (3), pp. 1067-1076. Date of Electronic Publication: 2024 Jul 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  2,678 results for ""MYELODYSPLASTIC syndromes""